EPCAM and hepatocellular carcinoma: Further studies demonstrate that markers such as CD133, EpCAM, and CK19 are overexpressed in HCC patients following transarterial chemoembolization (TACE) treatment, associating these elevated levels with poor prognosis, recurrence, and treatment resistance (125–127).